Endologix, Inc. (NASDAQ:ELGX) was downgraded by stock analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Friday.

Several other equities research analysts have also recently commented on the company. Canaccord Genuity reissued a “hold” rating on shares of Endologix in a report on Friday. Oppenheimer Holdings, Inc. set a $5.00 target price on Endologix and gave the stock a “hold” rating in a report on Thursday. Stifel Nicolaus set a $6.00 target price on Endologix and gave the stock a “hold” rating in a report on Wednesday. Royal Bank Of Canada reissued a “hold” rating and set a $5.00 target price on shares of Endologix in a report on Monday. Finally, Zacks Investment Research cut Endologix from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 25th. One investment analyst has rated the stock with a sell rating and eleven have issued a hold rating to the stock. Endologix currently has an average rating of “Hold” and a consensus target price of $6.28.

Endologix (NASDAQ:ELGX) traded down 4.023% during midday trading on Friday, hitting $4.175. The company had a trading volume of 2,023,964 shares. The company’s 50 day moving average is $4.91 and its 200 day moving average is $6.07. Endologix has a 12-month low of $4.17 and a 12-month high of $13.30. The stock’s market cap is $348.30 million.

Endologix (NASDAQ:ELGX) last announced its earnings results on Wednesday, August 2nd. The medical instruments supplier reported ($0.10) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.08. Endologix had a negative return on equity of 44.60% and a negative net margin of 40.77%. The firm had revenue of $48.60 million for the quarter, compared to analysts’ expectations of $47.58 million. During the same quarter in the previous year, the company earned ($0.20) earnings per share. The firm’s quarterly revenue was down 4.6% compared to the same quarter last year. On average, equities analysts anticipate that Endologix will post ($0.60) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Endologix, Inc. (ELGX) Cut to Sell at BidaskClub” was reported by Daily Political and is the property of of Daily Political. If you are accessing this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The original version of this article can be accessed at https://www.dailypolitical.com/2017/08/04/endologix-inc-elgx-cut-to-sell-at-bidaskclub.html.

In other Endologix news, Director Guido J. Neels purchased 20,000 shares of the firm’s stock in a transaction on Friday, May 19th. The shares were purchased at an average price of $4.32 per share, for a total transaction of $86,400.00. Following the completion of the transaction, the director now owns 61,380 shares in the company, valued at approximately $265,161.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Dan Lemaitre purchased 22,522 shares of the firm’s stock in a transaction on Monday, May 22nd. The stock was acquired at an average price of $4.43 per share, for a total transaction of $99,772.46. Following the transaction, the director now owns 68,689 shares of the company’s stock, valued at approximately $304,292.27. The disclosure for this purchase can be found here. In the last 90 days, insiders acquired 44,722 shares of company stock worth $195,676. 3.90% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of ELGX. Parametric Portfolio Associates LLC raised its position in Endologix by 30.0% in the first quarter. Parametric Portfolio Associates LLC now owns 89,748 shares of the medical instruments supplier’s stock valued at $650,000 after buying an additional 20,685 shares during the period. C WorldWide Group Holding A S raised its position in Endologix by 41.8% in the first quarter. C WorldWide Group Holding A S now owns 524,556 shares of the medical instruments supplier’s stock valued at $3,798,000 after buying an additional 154,556 shares during the period. Stoneridge Investment Partners LLC raised its position in Endologix by 142.4% in the first quarter. Stoneridge Investment Partners LLC now owns 196,344 shares of the medical instruments supplier’s stock valued at $1,422,000 after buying an additional 115,337 shares during the period. Great West Life Assurance Co. Can raised its position in Endologix by 6,604.0% in the first quarter. Great West Life Assurance Co. Can now owns 448,025 shares of the medical instruments supplier’s stock valued at $3,249,000 after buying an additional 441,342 shares during the period. Finally, Wells Fargo & Company MN raised its position in Endologix by 7.6% in the first quarter. Wells Fargo & Company MN now owns 157,990 shares of the medical instruments supplier’s stock valued at $1,144,000 after buying an additional 11,188 shares during the period.

Endologix Company Profile

Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.

Analyst Recommendations for Endologix (NASDAQ:ELGX)

Receive News & Ratings for Endologix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.